Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2017-A01524-49 | Other Identifier | ID-RCB |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Cerebral amyloid angiopathy (CAA) is a major cause of lobar intracerebral hemorrhage (ICH) in the elderly with high risk of recurrence.
The investigators aim to determine the relationship between cortical superficial siderosis (cSS), a MRI hemorrhagic marker of CAA and the risk of symptomatic ICH recurrence in a multicentric prospective cohort of patients with acute lobar ICH related to CAA. The investigators hypothesize that patients with cSS have an increased risk of recurrent symptomatic ICH relative to those without cSS.
Patients with acute lobar ICH fulfilling the Boston criteria for probable or possible CAA will be enrolled within 30 days after ICH onset. Brain MRI performed at baseline will be analyzed blinded to clinical data. Patients with presence of cSS will be compared with those without cSS.
During a systematic follow-up of 24 months, patients will undergo neurological, neuropsychological and MRI evaluation. The investigators will compare the rate of recurrent symptomatic ICH at 24 months in patients with vs. without cSS.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients with cortical superficial siderosis. | Other | During a systematic follow-up of 24 months, patients will undergo neurological, neuropsychological and MRI evaluation |
|
| Patients without cortical superficial siderosis | Other | During a systematic follow-up of 24 months, patients will undergo neurological, neuropsychological and MRI evaluation |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| neurological, neuropsychological and MRI evaluation | Other | neurological, neuropsychological and MRI evaluation |
|
| Measure | Description | Time Frame |
|---|---|---|
| Recurrent symptomatic intracerebral hemorrhage at 24 months | Recurrent symptomatic intracerebral haemorrhage is defined as a further intracerebral hemorrhage documented by CT scan or MRI, associated with new neurologic symptoms | 24 months |
| Measure | Description | Time Frame |
|---|---|---|
| Recurrent symptomatic ICH at 12 months | Recurrent symptomatic intracerebral haemorrhage is defined as a further intracerebral hemorrhage documented by CT scan or MRI, associated with new neurologic symptoms. | 12 months |
| Transient Focal Neurological Episodes (TFNE) at 12 and 24 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Nicolas RAPOSO, MD | University Hospital, Toulouse | Principal Investigator |
| Lionel CALVIERE | University Hospital, Toulouse | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pellegrin Hospital | Bordeaux | France | ||||
| Gui de Chauliac Hospital |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D016657 | Cerebral Amyloid Angiopathy |
| D002543 | Cerebral Hemorrhage |
| ID | Term |
|---|---|
| D002539 | Cerebral Arterial Diseases |
| D020765 | Intracranial Arterial Diseases |
| D002561 | Cerebrovascular Disorders |
| D001927 | Brain Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
TFNE was defined as transient (≤24 hours), with fully resolving, focal neurological symptoms that had no known alternative explanation other than CAA (e.g., structural brain lesion, atrial fibrillation, extracranial, or intracranial stenosis) |
| 12 and 24 months |
| mortality or dependance at 12 and 24 months | Mortality and dependence defined by a modified Rankin scale >2 | 12 and 24 months |
| Cognitive decline at 12 and 24 months | moderate or severe vascular cognitive disorders (VCD) according to the VASCOG criteria. | 12 and 24 months |
| New MRI hemorrhagic lesion at 12 months | Presence of new symptomatic or asymptomatic hemorrhagic lesion (ICH, microbleeds, convexity subarachnoid hemorrhage) on follow-up MRI at 12 months | 12 months |
| Extent of cortical superficial siderosis at 12 months | Extent of cSS is assessed on follow up MRI at 12 months according to the current guidelines: 0: no cSS; 1: focal cSS (restricted to ≤3 sulci); 2: disseminated cSS (≥4 sulci). | 12 months |
| frequency of APOE ε2 and ε4 allele | frequency of both ε2 and ε4 allele on Apolipoprotein E (APOE) genotype at baseline | baseline |
| Montpellier |
| France |
| Lariboisière Hospital | Paris | France |
| CHU Purpan. Hôpital Pierre-Paul Riquet | Toulouse | 31059 | France |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D000686 | Amyloidosis |
| D057165 | Proteostasis Deficiencies |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D020300 | Intracranial Hemorrhages |
| D006470 | Hemorrhage |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |